Current Headlines

  1. AbCellera Announces Multi-Year Antibody Discovery Collaboration With Lilly 5/22/2020

    AbCellera announced today that it has entered into a multi-year strategic research collaboration and license agreement with Eli Lilly and Company (Lilly) on the discovery of antibodies for up to nine Lilly-selected therapeutic targets

  2. More Efficient Drug Development With The Help Of Computer Models 5/21/2020

    The coronavirus has the world in its grip. Finding a cure has never been more important. Unfortunately, the development of new drugs for treatment of the COVID-19 disease caused by the virus and development of a vaccine are complex, lengthy, and above all costly processes

  3. FDA Approves Octapharma USA Investigational New Drug Application For Severe COVID-19 Patients 5/20/2020

    The U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application submitted by Octapharma USA for a phase three clinical trial on the efficacy and safety of Octagam 10% [Immune Globulin Intravenous (Human)] therapy in COVID-19 patients with severe disease progression

  4. iSpecimen And myOnsite HealthCare Deploy Mobile Phlebotomy To Help Advance Research During The Coronavirus Pandemic 5/20/2020

    iSpecimen today announced a new initiative in the battle against COVID-19 and other diseases – mobile phlebotomy support that will bring convenient, at-home sample collection to patients and donors interested in advancing research who would otherwise have limited ability to participate.

  5. An Open-Access Tool To Accelerate Drug Discovery 5/19/2020

    Knowledge of how a molecule interacts with the organism is crucial in order to consider its therapeutic potential. Headed by ICREA researcher Patrick Aloy, the Structural Bioinformatics and Network Biology (SBNS) lab at IRB Barcelona has presented the Chemical Checker, an on-line open-access tool that provides information on the effects exerted by more than 1M compounds in a wide range of biological settings

  6. Glemser Technologies And Arria NLG Announce Strategic Partnership 5/19/2020

    Arria NLG, a leading provider of Natural Language Generation (NLG) technology, today announced a collaboration with Glemser Technologies to bring scalable automation solutions and major efficiencies to healthcare and pharmaceuticals companies

  7. QPS Continues To Expand UPLC-HRMS Quantitation Capabilities To Support Gene Therapy And Protein Drug Development 5/19/2020

    QPS, a global contract research organization (CRO) that provides discovery, preclinical, and clinical drug development services, is reinforcing its focus on qualitative and quantitative bioanalysis of biotherapeutics

  8. Excelra To Provide Lawrence Livermore National Laboratory With Small Molecule Medicinal Chemistry Intelligence Data To Help Develop Drug Design Platform 5/19/2020

    Under a three-year agreement, Excelra – a leading global data and analytics company – will provide Lawrence Livermore National Laboratory (LLNL) with GOSTAR, a small molecule medical chemistry intelligence database to aid drug design projects

  9. Vividion Therapeutics Announces Drug Discovery Collaboration With Roche Focused On Novel E3 Ligases 5/19/2020

    Vividion Therapeutics, a biotechnology company discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, today announced that it has entered into an exclusive worldwide option and license agreement with Roche (SIX: RO, ROG;OTCQX: RHHBY) to leverage its proteomics screening platform and proprietary small molecule library to target novel E3 ligases, as well as a range of oncology and immunology therapeutic targets

  10. FDA Clears The Investigational New Drug Application To Enable The Phase II Trial Of Viralclear’s Merimepodib, Oral Solution To Treat Adult Patients With Advanced COVID-19, To Proceed 5/18/2020

    BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announced that the U.S. Food and Drug Administration (FDA) has completed its review of ViralClear’s Investigational New Drug (IND) application